Alidhe

A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy
Description: The purpose of this study is to learn more about the safety and efficacy of the medication ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a particular gene mutation called IDH1 (isocitrate dehydrogenase1)
Study Phase: Phase 3
Principal Investigator: Dr Nina Orfali
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry

Hovon-173

Ivosidenib and Azacitidine With or Without Venetoclaxin Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML considered Ineligible for Intensive Chemotherapy
Description: In this study it is investigated whether adding venetoclax to the standard treatment can improve the outcome of the treatment of this specific form of AML. The safety is investigated and how well it works.
Study Phase: Phase 3
Principal Investigator:
Further information

Hovon-177

Randomized study assessing azacitidine and venetoclaxwith or without revumenibin adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy
Description: This study is testing a new combination of medicines for older adults with a specific type of blood cancer (Acute Myeloid Leukemia - AML).
Study Phase: Phase 3
Principal Investigator: Dr Nina Orfali
Further information